Edit Entry | Edit CV

Todd W Miller, PhD

Title(s)
Associate Professor of Molecular and Systems Biology

Additional Titles/Positions/Affiliations
Co-Director, Cancer Signaling, Genomes & Networks Research Program, Dartmouth Cancer Center
Scientific Director, Comprehensive Breast Program, Dartmouth Cancer Center
Co-Director, Molecular Tumor Board, Dartmouth Cancer Center

Department(s)
Molecular and Systems Biology

Education
University of Connecticut (Storrs, CT), B.S., Physiology & Neurobiology, 1998
University at Albany (Albany, NY), Ph.D. in Biomedical Sciences, 2004
Vanderbilt University (Nashville, TN), Post-doctoral Fellowship in Breast Cancer, 2004-2009

Programs
Molecular and Cellular Biology Graduate Programs
Norris Cotton Cancer Center

Websites
Lab website:
https://millerlaboratory.org/

Publications:
http://www.ncbi.nlm.nih.gov/sites/myncbi/todd.miller.1/bibliography/42064063/public/?sort=date&direction=descending

Contact Information

1 Medical Center Drive
Rubin Bldg, HB 7936
Lebanon NH 03756

Office: Rubin 604
Phone: 603-646-5507
Email: Todd.W.Miller@Dartmouth.edu


Professional Interests

Breast cancer, targeted therapeutics, signaling pathways, drug resistance, biomarker development

Biography

Dr. Miller received his B.S. in Physiology and Neurobiology at the University of Connecticut in 1998, and his Ph.D. in Biomedical Sciences at the State University of New York at Albany in 2004 (thesis: Immunization and single-chain Fv intrabody gene therapies for Huntington’s Disease). He did his postdoctoral training at Vanderbilt University (2004-2009), and served as a Research Faculty member 2009-2012. Dr. Miller joined the Geisel School of Medicine at Dartmouth in 2012.


Selected Publications

 

The role of cancer cell bioenergetics in dormancy and drug resistance.
Tau S, Miller TW
Cancer Metastasis Rev. 2023 Jan 25; doi: 10.1007/s10555-023-10081-7. Epub 2023 Jan 25.
PMID: 36696004

Alpelisib Efficacy Without Cherry-PI3King Mutations.
Tau S, Miller TW
Clin Cancer Res. 2023 Jan 10; pii: CCR-22-3411. doi: 10.1158/1078-0432.CCR-22-3411. Epub 2023 Jan 10.
PMID: 36626159

Tumour, whole-blood, plasma and tissue concentrations of metformin in lung cancer patients.
Phillips JD, Pooler DB, Ness DB, Fay K, Tau S, Demidenko E, Hampsch RA, Lewis LD, Miller TW
Br J Clin Pharmacol. 2022 Sep 26; doi: 10.1111/bcp.15546. Epub 2022 Sep 26.
PMID: 36164710

High estrogen receptor alpha activation confers resistance to estrogen deprivation and is required for therapeutic response to estrogen in breast cancer.
Traphagen NA, Hosford SR, Jiang A, Marotti JD, Brauer BL, Demidenko E, Miller TW
Oncogene. 2021 May;40(19):3408-3421. doi: 10.1038/s41388-021-01782-w. Epub 2021 Apr 19.
PMID: 33875787

Pan-Cancer Transcriptional Models Predicting Chemosensitivity in Human Tumors.
Wells JD, Griffin JR, Miller TW
Cancer Inform. 2021;20:11769351211002494. doi: 10.1177/11769351211002494. Epub 2021 Mar 19.
PMID: 33795931

Changes in Peripheral and Local Tumor Immunity after Neoadjuvant Chemotherapy Reshape Clinical Outcomes in Patients with Breast Cancer.
Axelrod ML, Nixon MJ, Gonzalez-Ericsson PI, Bergman RE, Pilkinton MA, McDonnell WJ, Sanchez V, Opalenik SR, Loi S, Zhou J, Mackay S, Rexer BN, Abramson VG, Jansen VM, Mallal S, Donaldson J, Tolaney SM, Krop IE, Garrido-Castro AC, Marotti JD, Shee K, Miller TW, Sanders ME, Mayer IA, Salgado R, Balko JM
Clin Cancer Res. 2020 Nov 1;26(21):5668-5681. doi: 10.1158/1078-0432.CCR-19-3685. Epub 2020 Aug 21.
PMID: 32826327

Identification of Let-7f-5p as a novel biomarker of recurrence in non-muscle invasive bladder cancer.
Shee K, Seigne JD, Karagas MR, Marsit CJ, Hinds JW, Schned AR, Pettus JR, Armstrong DA, Miller TW, Andrew AS
Cancer Biomark. 2020;29(1):101-110. doi: 10.3233/CBM-191322.
PMID: 32623385

Molecular matching and treatment strategies for advanced stage lung cancer at Dartmouth-Hitchcock Medical Center: A three-year review of a Molecular Tumor Board.
Bernhardt EB, Chamberlin MD, Gorlov IP, de Abreu FB, Bloch KJ, Peterson JD, Tsongalis GJ, Shirai K, Dragnev KH, Miller TW, Tafe LJ
Pract Lab Med. 2020 Aug;21:e00174. doi: 10.1016/j.plabm.2020.e00174. Epub 2020 Jun 12.
PMID: 32613070

Plasma DNA as a "liquid biopsy" incompletely complements tumor biopsy for identification of mutations in a case series of four patients with oligometastatic breast cancer.
Chamberlin MD, Wells JD, Shee K, Bean JR, Marotti JD, Wells WA, Trask HW, Kolling FW, Bhatt A, Kaufman PA, Schwartz GN, Gemery JM, McNulty NJ, Tsapakos MJ, Barth RJ, Arrick BA, Gui J, Miller TW
Breast Cancer Res Treat. 2020 Aug;182(3):665-677. doi: 10.1007/s10549-020-05714-2. Epub 2020 Jun 19.
PMID: 32562118

AMPK Activation by Metformin Promotes Survival of Dormant ER(+) Breast Cancer Cells.
Hampsch RA, Wells JD, Traphagen NA, McCleery CF, Fields JL, Shee K, Dillon LM, Pooler DB, Lewis LD, Demidenko E, Huang YH, Marotti JD, Goen AE, Kinlaw WB, Miller TW
Clin Cancer Res. 2020 Jul 15;26(14):3707-3719. doi: 10.1158/1078-0432.CCR-20-0269. Epub 2020 Apr 22.
PMID: 32321715

View more publications on PubMed